# Azitra, Inc.: overview

AZTR · NYSE · CIK 1701478 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aztr.md) · [Financials](/companies/aztr/financials.md) · [Filings](/companies/aztr/filings.md) · [Insiders](/companies/aztr/insiders.md)

Latest reported revenue: [$0](/filings/0001701478-26-000013.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Feb 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001701478-26-000013).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001701478-25-000050.md) | [0.0 d](/filings/0001701478-26-000013.md) | not reported | [0.0](/filings/0001701478-25-000040.md) | [0.0](/filings/0001701478-25-000050.md) | [0.0 d](/filings/0001701478-26-000013.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.14)](/filings/0001701478-25-000050.md) | not reported | [(1.55)](/filings/0001701478-26-000028.md) | [(1.18)](/filings/0001701478-26-000037.md) | [(0.67)](/filings/0001701478-25-000050.md) | not reported | [(0.25)](/filings/0001701478-26-000028.md) | [(0.17)](/filings/0001701478-26-000037.md) |
| Free cash flow | $k | [(2,484) d](/filings/0001701478-25-000050.md) | [(2,586) d](/filings/0001701478-26-000013.md) | [(3,072)](/filings/0001701478-26-000028.md) | [(2,827) d](/filings/0001701478-26-000037.md) | [(2,448) d](/filings/0001701478-25-000050.md) | [(2,902) d](/filings/0001701478-26-000013.md) | [(2,492)](/filings/0001701478-26-000028.md) | [(3,331) d](/filings/0001701478-26-000037.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0001493152-24-010091.md) | [0.7](/filings/0001701478-25-000012.md) | [0.0](/filings/0001701478-26-000013.md) | [0.0](/filings/0001701478-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | [(3328.7%)](/filings/0001493152-24-010091.md) | [(1086.1%)](/filings/0001701478-25-000012.md) | [(146468.5%)](/filings/0001701478-26-000013.md) | not reported |
| Net margin | % | [(3760.7%)](/filings/0001493152-24-010091.md) | [(1644.9%)](/filings/0001701478-25-000012.md) | [(119566.6%)](/filings/0001701478-26-000013.md) | not reported |
| Diluted EPS | $ per share | [(12.74)](/filings/0001493152-24-010091.md) | [(54.98)](/filings/0001701478-25-000012.md) | [(15.70)](/filings/0001701478-26-000013.md) | [(2.25)](/filings/0001701478-26-000013.md) |
| Free cash flow | $m | [(8.4)](/filings/0001493152-24-010091.md) | [(7.4)](/filings/0001701478-25-000012.md) | [(10.2)](/filings/0001701478-26-000013.md) | [(11.2)](/filings/0001701478-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aztr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $1.9m | 11,292,186 |  | Added +11,291,186 |
| [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $886.9k | 5,285,476 |  | New +5,285,476 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $371.4k | 2,213,613 |  | New +2,213,613 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $371.4k | 2,213,613 |  | New +2,213,613 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $41.7k | 248,433 |  | New +248,433 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $16.0k | 95,409 |  | Reduced −374,469 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $14.5k | 86,242 |  | New +86,242 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $8.5k | 50,481 |  | Added +20,276 |
| [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $5.0k | 28,651 |  | Added +6,187 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.3k | 19,500 |  | Added +4,415 |

## Recent filings

[All 237 filings](/companies/aztr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 08:35 ET | [8-K](/filings/0001493152-26-049191.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-049191 |
| 2026-10-26 | 08:50 ET | [8-K](/filings/0001493152-26-048431.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-048431 |
| 2026-10-22 | 16:15 ET | [8-K](/filings/0001493152-26-048103.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-048103 |
| 2026-10-01 | 08:10 ET | [8-K](/filings/0001493152-26-045260.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-045260 |
| 2026-09-28 | 16:50 ET | [8-K](/filings/0001493152-26-044605.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-044605 |
| 2026-09-08 | 08:05 ET | [8-K](/filings/0001493152-26-041706.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041706 |
| 2026-08-21 | 08:05 ET | [8-K](/filings/0001493152-26-039565.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-039565 |
| 2026-08-12 | 16:55 ET | [8-K](/filings/0001701478-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001701478-26-000039 |
| 2026-08-12 | 16:54 ET | [10-Q](/filings/0001701478-26-000037.md) | Quarterly report, period 2026-06-30 | 0001701478-26-000037 |
| 2026-07-15 | 16:10 ET | [8-K](/filings/0001493152-26-033358.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-033358 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001701478-26-000013.md), filed Feb 27, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1701478
- Tickers: AZTR
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:36 ET. No prices; not investment advice.